JP2022513933A5 - - Google Patents
Info
- Publication number
- JP2022513933A5 JP2022513933A5 JP2021534641A JP2021534641A JP2022513933A5 JP 2022513933 A5 JP2022513933 A5 JP 2022513933A5 JP 2021534641 A JP2021534641 A JP 2021534641A JP 2021534641 A JP2021534641 A JP 2021534641A JP 2022513933 A5 JP2022513933 A5 JP 2022513933A5
- Authority
- JP
- Japan
- Prior art keywords
- disorders
- compound according
- disorder
- status epilepticus
- salt form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862780703P | 2018-12-17 | 2018-12-17 | |
| US62/780,703 | 2018-12-17 | ||
| PCT/US2019/066923 WO2020131918A1 (en) | 2018-12-17 | 2019-12-17 | Organic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513933A JP2022513933A (ja) | 2022-02-09 |
| JP2022513933A5 true JP2022513933A5 (enExample) | 2022-12-23 |
| JP7645797B2 JP7645797B2 (ja) | 2025-03-14 |
Family
ID=71100855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534641A Active JP7645797B2 (ja) | 2018-12-17 | 2019-12-17 | 有機化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12325726B2 (enExample) |
| EP (1) | EP3897656A4 (enExample) |
| JP (1) | JP7645797B2 (enExample) |
| KR (1) | KR102931436B1 (enExample) |
| CN (1) | CN113226326B (enExample) |
| AU (1) | AU2019406803B2 (enExample) |
| BR (1) | BR112021011765A2 (enExample) |
| CA (1) | CA3121636A1 (enExample) |
| IL (1) | IL283960B2 (enExample) |
| MX (1) | MX2021007142A (enExample) |
| WO (1) | WO2020131918A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| MX2021007142A (es) | 2018-12-17 | 2021-08-11 | Intra Cellular Therapies Inc | Compuestos organicos. |
| WO2021168106A1 (en) * | 2020-02-18 | 2021-08-26 | Praxis Precision Medicines, Inc. | Deuterated neurosteroid |
| JP2023539125A (ja) * | 2020-08-20 | 2023-09-13 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| WO2023159094A2 (en) * | 2022-02-16 | 2023-08-24 | Praxis Precision Medicines, Inc. | PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| ES2296594T3 (es) | 1994-02-14 | 2008-05-01 | Euro-Celtique S.A. | Androstanos y pregnanos para la modulacion alosterica del receptor de gaba. |
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| UA73736C2 (en) * | 1999-04-29 | 2005-09-15 | Euro Celtic S A | Method for alleviating or preventing insomnia and inducing anesthesia |
| WO2005105822A2 (en) | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| US20060074059A1 (en) | 2004-08-26 | 2006-04-06 | Goliber Philip A | Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one |
| ATE538797T1 (de) | 2005-06-09 | 2012-01-15 | Euro Celtique Sa | Pharmazeutische zusammensetzungen mit neuroaktivem steroid und verwendungen davon |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| CN117024501A (zh) * | 2014-10-16 | 2023-11-10 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| ME03809B (me) * | 2014-10-16 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a |
| CN105985396A (zh) | 2015-02-16 | 2016-10-05 | 苏州泽璟生物制药有限公司 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
| EP4155314A1 (en) | 2015-02-20 | 2023-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| MX2021007142A (es) | 2018-12-17 | 2021-08-11 | Intra Cellular Therapies Inc | Compuestos organicos. |
| JP2023539125A (ja) | 2020-08-20 | 2023-09-13 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
-
2019
- 2019-12-17 MX MX2021007142A patent/MX2021007142A/es unknown
- 2019-12-17 AU AU2019406803A patent/AU2019406803B2/en active Active
- 2019-12-17 JP JP2021534641A patent/JP7645797B2/ja active Active
- 2019-12-17 WO PCT/US2019/066923 patent/WO2020131918A1/en not_active Ceased
- 2019-12-17 EP EP19899589.6A patent/EP3897656A4/en active Pending
- 2019-12-17 CA CA3121636A patent/CA3121636A1/en active Pending
- 2019-12-17 KR KR1020217022377A patent/KR102931436B1/ko active Active
- 2019-12-17 US US17/415,667 patent/US12325726B2/en active Active
- 2019-12-17 CN CN201980083634.9A patent/CN113226326B/zh active Active
- 2019-12-17 BR BR112021011765-2A patent/BR112021011765A2/pt unknown
- 2019-12-17 IL IL283960A patent/IL283960B2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022513933A5 (enExample) | ||
| JP2023539125A5 (enExample) | ||
| JP2023527575A5 (enExample) | ||
| JP2021519267A5 (enExample) | ||
| RU2012127770A (ru) | Полициклические соединения и способы их применения | |
| CA2636324A1 (en) | Cycloalkylamines as monoamine reuptake inhibitors | |
| JP2022535093A (ja) | 重水素化された又は部分的に重水素化されたｎ，ｎ－ジメチルトリプタミン化合物を含む治療用組成物 | |
| JP2017531020A5 (enExample) | ||
| JP2018104454A5 (enExample) | ||
| KR100630981B1 (ko) | 알파-2-델타-단백질에 대한 친화성을 갖는 아미노산 | |
| JP2018505898A5 (enExample) | ||
| RU2007119585A (ru) | Производные рапамицина и их применение при лечении неврологических заболеваний | |
| JP2004507500A5 (enExample) | ||
| US5552418A (en) | Trisubstituted Naphthylalkylamides | |
| JP2009527462A5 (enExample) | ||
| RU2009143104A (ru) | Новые двузамещенные фенилпирролидины в качестве модуляторов кортикальной катехоламинергической нейротрансмиссии | |
| RU2008100019A (ru) | Способ лечения чрезмерной дневной сонливости (варианты) | |
| EP4457222A2 (en) | Nitric oxide releasing prodrugs of mda and mdma | |
| JP2023509798A5 (enExample) | ||
| EP3908570A1 (en) | Ketamine pamoate and use thereof | |
| JP2018508592A5 (enExample) | ||
| JP2024531437A5 (enExample) | ||
| RU2013147917A (ru) | Новые модуляторы кортикальной дофаминергической и опосредованной nmda-рецептором глутаматергической нейротрансмиссии | |
| JP2014518552A5 (enExample) | ||
| RU2016132574A (ru) | Органические соединения |